GSK and Vir announced on Wednesday that sotrovimab, a monoclonal antibody used in the treatment of Covid-19 that the two companies developed together, has been granted Emergency Use Authorization by the U.S. FDA.
Sotrovimab was authorized for use in adults and children over 12 who are at high risk of developing severe Covid-19 due to age, medical history or other factors.
The drug is given to people before they are hospitalized, and led to an 85% reduction in hospitalizations and death among patients with Covid-19.
This is the third monoclonal antibody therapy that has been granted an EUA, following drugs from Regeneron and Lilly.
The FDA says that the GSK/Vir antibody remains effective against known Covid-19 variants that originated in the U.K., South Africa,…